Zimislecel is an allogeneic stem cell-derived islet cell therapy that could eliminate the need for insulin in those who have type 1 diabetes. Regulatory submissions are expected in 2026, and if ...

Other medications called SGLT2 inhibitors (gliflozins) may increase the risk of a potentially fatal condition called diabetic ketoacidosis. The medication, in combination with another trigger such as ...